New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 13, 2014
07:39 EDTABBV, ENTAEnanta Pharmaceuticals says starting FY14 with 'strong' cash position
The company said, “Enanta (ENTA) is beginning FY14 with a strong cash position and four compounds in the clinic. Our partner AbbVie (ABBV) recently completed the largest phase 3 program to date for an all-oral, genotype 1 hepatitis C virus treatment regimen, and it expects to launch the regimen in FY14. AbbVie’s tested regimen includes our collaboration’s lead protease compound ABT-450. In addition, we continue to explore new infectious disease areas and have recently initiated a phase 1 study of our proprietary bicyclolide candidate EDP-788 which we are developing for MRSA.”
News For ENTA;ABBV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 23, 2015
16:06 EDTENTAEnanta reports Q4 EPS 29c, consensus 15c
Subscribe for More Information
15:28 EDTENTANotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Palo Alto (PANW), consensus 32c... Copart (CPRT), consensus 43c... Brocade (BRCD), consensus 24c... Post Holdings (POST), consensus 29c... YY (YY), consensus 82c... Dycom (DY), consensus $1.01... Cubic (CUB), consensus 96c... Enanta (ENTA), consensus 15c.
November 19, 2015
07:36 EDTABBVFDA Pediatric Advisory Committee to hold a meeting
Subscribe for More Information
November 18, 2015
07:43 EDTABBVJefferies to hold a conference
Subscribe for More Information
November 17, 2015
10:09 EDTABBVAbbVie management to meet with Jefferies
Subscribe for More Information
08:05 EDTABBVInfinity reaches target enrollment in Phase 3 study of duvelisib
Subscribe for More Information
November 16, 2015
17:02 EDTABBVPoint72 added to lululemon position, subtracted from Netflix position
Subscribe for More Information
09:11 EDTENTAEnanta says ABT-493 study data show 'high sustained' response rates
Enanta Pharmaceuticals announced data from AbbVie's SURVEYOR studies of its investigational treatment regimen, consisting of ABT-493, an NS3/4A protease inhibitor, and ABT-530, an NS5A inhibitor, that show high rates of sustained virologic response at 12 weeks post-treatment in non-cirrhotic patients with chronic hepatitis C virus infection. After 12 weeks of treatment, SVR12 rates achieved were 97%-100% in genotype 1 patients, 96-100 percent in genotype 2, and 83%-94% in genotype 3. These data will be presented at The Liver Meeting, which is the Annual Meeting of the American Association for the Study of Liver Diseases in San Francisco. Separately, in a late-breaking presentation of the SURVEYOR-1 trial, additional data will show non-cirrhotic GT1 chronic HCV patients who received a shorter duration of treatment for 8 weeks with ABT-493 and ABT-530 achieved a SVR rate of 97%.
09:04 EDTABBVAbbVie announecs data from Surveyor studies of ABT-493
Subscribe for More Information
November 15, 2015
14:30 EDTENTA, ABBVEnanta confirms interim Phase 3b data on Viekira Pak
Subscribe for More Information
14:23 EDTABBVAbbVie reports Phase 3b data on Viekira Pak for hepatitis C
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use